xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

234

KUANetal.

TABLE XXIII.B.2 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Sinonasal OsS a : 9/15 (0)

Demicco

2010 4

Retrospective case series

OS

1. Low-grade OsS are effectively treated with wide surgery alone 2. 5-year OS: 100% d 1. Early diagnosis and adequate treatment consisting of R0 surgery with RT and/or chemotherapy are essential to improve outcomes 2. 2- and 5-year OS: 100% d and 90.0% d , respectively 3. 2- and 5-year RFS: 44.9% d and 29.9% d , respectively treatment in craniofacial OsS 2. Adjuvant RT is indicated in case of margin involvement/unclear status 1. Failure to achieve local control is associated with poor survival 2. 5- and 10-year OS: ∼ 75% c and ∼ 65%, c respectively treatment in craniofacial OsS 2. Adjuvant RT is indicated in case of adverse factors such as margin involvement R0 surgery and high-dose chemotherapy represent the most effective treatment strategy for craniofacial OsS Surgery with postoperative chemotherapy for high-grade OsS is an adequate treatment strategy frequently of high grade and associated with worse prognosis 2. 5-year OS: 100% 1. Post-RT OsS in patients treated for NPC is associated with dismal prognosis 2. Surgery combined with pre- and postoperative chemotherapy could be a valuable treatment strategy 1. 1- and 2-year OS: 80.8% d 2. 5-year OS: 21.5% d Six (50.0%) local recurrences, one (8.3%) distant recurrence 1. Margin involvement is the only factor affecting OS and CSS in craniofacial OsS 2. 3-year local control rate: 50%–78% (Continues) 1. Surgery is the mainstay of 1. Surgery is the mainstay of 1. Osteolytic OsS are more

et al. 1274

Sinonasal OsS a : 21/21 (1)

Luna-Ortiz et al. 1275

2010 4

Retrospective case series

1. OS 2. RFS

Sinonasal OsS a : 54/119 b (16)

2009 4

Retrospective case series

Guadagnolo et al. 1283

1. OS 2. CSS 3. RFS

Jasnau et al. 1272

Sinonasal OsS a : 12/49 b

2008 4

Retrospective case series

1. OS 2. RFS

Laskar et al. 1273

Sinonasal OsS a : 21/50 b (0)

2008 4

Retrospective case series

OS

Thiele et al. 1291

Sinonasal OsS a : 7/12 b (0)

2008 4

Retrospective case series

OS

Sinonasal OsS a : 7/16 b (1)

Fernandes et al. 1271

2007 4

Retrospective case series

OS

Sinonasal OsS a : 5/10 (2)

Nakayama et al. 1269

2005 4

Retrospective case series

OS

Sinonasal OsS a : 8/15 (15)

Liuet al. 1270

2005 4

Retrospective case series

OS

Sinonasal OsS a : 12/12 OS

Panda et al. 1268

2003 4

Retrospective case series

Patel et al. 1267

Sinonasal OsS a : 26/44 (6)

2002 4

Retrospective case series

1. OS 2. CSS